ReviewAging medicine (Milton (N.S.W))2026
Biomarkers of Sarcopenia: Current Status and Future Perspectives.
Review in Aging medicine (Milton (N.S.W)), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is an age-related skeletal muscle disorder characterized by progressive declines in muscle mass, strength, and physical function, which profoundly impair quality of life in older adults. Although current clinical guidelines propose various diagnostic approaches and cutoff values, considerable heterogeneity among criteria and assessment tools continues to pose challenges for the accurate and early diagnosis of sarcopenia. In recent years, an increasing number of studies have identified potential biomarkers associated with sarcopenia, which can be broadly classified into biochemical, imaging-based, and physical performance-related categories. The identification of these biomarkers has improved diagnostic accuracy, provided additional means for monitoring disease progression, and opened new avenues for therapeutic intervention. This narrative review aims to summarize currently established and emerging biomarkers related to sarcopenia, with a particular focus on their biological relevance, clinical applicability, and limitations. Furthermore, potential directions for future research are discussed to facilitate the development of integrated, multimodal biomarker strategies for the early detection, risk stratification, and personalized management of sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.